Ophthotech raises $175m for Fovista Phase III in wet AMD
This article was originally published in Scrip
Executive Summary
Ophthotech raised $175 million, mostly in the form of royalty financing from Novo A/S, to fund a 1,900-patient Phase III clinical trial for its anti-platelet-derived growth factor (anti-PDGF) aptamer Fovista in combination with an anti-VEGF therapy for the treatment of wet age-related macular degeneration (AMD).